Breast Reconstruction Autologous with Implant in Chula Vista CA
Breast Reconstruction Autologous with Implant in Chula Vista section, includes general infrmation about Breast Reconstruction Autologous with Implant Procedure, Breast Reconstruction Autologous with Implant Chula Vista Local News, Breast Reconstruction Autologous with Implant Chula Vista Surgeon Locator and other Breast Reconstruction Autologous with Implant related material.
Breast Reconstruction Autologous with Implant Procedure
Breast reconstruction is a surgical procedure usually designed to reconstruct the breast of patients who have had a mastectomy due to breast cancer. Depending upon the patient, there may be several different options for breast reconstruction involving breast implants as well as using the patient's own tissues. Not every patient will be a candidate for every reconstructive technique.
Autologous tissue is tissue taken from another part of your body. This animation shows a breast reconstruction that is performed at a later date than the mastectomy. Sometimes a breast reconstruction may take place during the mastectomy.
An incision is made along the previous scar and dissection is carried down through the tissues to the chest wall.
Tissue from the abdomen or the back is dissected from its normal location and rotated into the mastectomy site to re-create the new breast. Important blood vessels are left attached and intact to provide blood to the tissue.
An implant is placed underneath the autologous tissue to increase the size of the reconstructed breast.
The nipple and areola are reconstructed with either local tissue and tattooing or a skin graft from your inner thigh.
Autologous reconstruction with an implant may be a good option in certain candidates; however, this can only be determined after consultation with your surgeon. Depending on the reconstructive technique utilized, the healing time can be from four to eight weeks or longer. If the abdominal tissue is utilized, the healing process will be longer. If the muscle from the back is used, the healing time is usually shorter. Breast reconstruction is a complex procedure and results vary.
The patient is placed in a compression garment or bra. Compression garments are an important part of the recovery process. The garment provides support, comfort and helps to minimize swelling. The patient is usually wearing a bra or some type of supportive garment at all times, except when showering. Healing time is approximately three months. Scarring is variable and often depends on the patient's ability to heal.
Other Breast Reconstruction Autologous with Implant Procedures
All Breast Procedures
Breast Reconstruction Autologous with Implant chula-vista (current)
chula-vista Breast Lift
chula-vista Breast Implants
chula-vista Implant Removal
chula-vista Armpit Incision
More Chula Vista info...
Chula Vista By Aeroplane Accessible by San Diego International Airport. McClellan-Palomar Airport (Carlsbad), John Wayne Airport (Santa Ana), Daugherty Field (Long Beach), Los Angeles International, Burbank International, Ontario International, or Palm Springs International all within 2.5 hour/300 mi. radius.
Chula Vista Get out This article is an outline and needs more content. It has a template, but there is not enough information present. Please plunge forward and help it grow!
Plastic Surgery News...
- Springer and the International Society for Cardiovascular Translational Research (ISCTR) are founding a new, quarterly biomedical publication called the Journal of Cardiovascular Translational Research (JCTR).
Context The erythropoiesis-stimulating agents (ESAs) erythropoietin and darbepoetin are licensed to treat chemotherapy-associated anemia in patients with nonmyeloid malignancies. Although systematic overviews of trials have identified venous thromboembolism (VTE) risks, none have identified mortality risks with ESAs.
Objective To evaluate VTE and mortality rates associated with ESA administration for the treatment of anemia among patients with cancer.
Data Sources A published overview from the Cochrane Collaboration (search dates: January 1, 1985-April 1, 2005) and MEDLINE and EMBASE databases (key words: clinical trial, erythropoietin, darbepoetin, and oncology), the public Web site of the US Food and Drug Administration and ESA manufacturers, and safety advisories (search dates: April 1, 2005-January 17, 2008).
Study Selection Phase 3 trials comparing ESAs with placebo or standard of care for the treatment of anemia among patients with cancer.
Data Extraction Mortality rates, VTE rates, and 95% confidence intervals (CIs) were extracted by 3 reviewers from 51 clinical trials with 13 611 patients that included survival information and 38 clinical trials with 8172 patients that included information on VTE.
Data Synthesis Patients with cancer who received ESAs had increased VTE risks (334 VTE events among 4610 patients treated with ESA vs 173 VTE events among 3562 control patients; 7.5% vs 4.9%; relative risk, 1.57; 95% CI, 1.31-1.87) and increased mortality risks (hazard ratio, 1.10; 95% CI, 1.01-1.20).
Conclusions Erythropoiesis-stimulating agent administration to patients with cancer is associated with increased risks of VTE and mortality. Our findings, in conjunction with basic science studies on erythropoietin and erythropoietin receptors in solid cancers, raise concern about the safety of ESA administration to patients with cancer.